A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

• Status: Completed
• Trial end date: 2015-02-05
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan

Criteria

Inclusion Criteria:

• Meibomian gland dysfunction in both eyes

• Best-corrected visual acuity of 20/40 or better in each eye

Exclusion Criteria:

• Known or suspected prostate cancer

• History of breast cancer

• Using LATISSE® or any other eye lash growth-stimulating product at least 30 days prior to the screening visit, or anticipated use during the study

• Contact lens wear in either eye during any portion of the study

• Unable to instill eye drops correctly

• History of corneal refractive surgery in either eye within 1 year